As of June 2026, PAHC's current EPS stands at $2.34, according to the latest financial reports. For the year 2025, the company recorded an earnings per share (EPS) of $1.19, which marks an increase compared to its EPS of $0.06 in 2024. PAHC reported an EPS of $0.59 for the quarterly report ending on Mar 31, 2026.
For 2025, Phibro Animal Health's EPS was $1.19, an increase of 1,883.3% from $0.06 in 2024. For the fiscal quarter that ended on Mar 31, 2026, the per-share earnings was $0.59, showing a 13.5% increase from the same quarter last year. For the twelve months ending March 2026, the EPS is $2.34. For the year 2024, the yearly earnings per share was $0.06, marking a decrease of 92.6% from 2023.
During the last 12 months, Phibro Animal Health has seen an EPS growth of 13.5% (YoY, quarterly). Examining a broader timeline, the company maintained an average EPS growth rate of -0.6% per year for the last three years. During the last 5 years, the company had an average EPS growth rate of 7.5%. A 10-year view shows that PAHC has seen an average EPS growth of -2.6% per year.
| Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
|---|---|---|---|---|
| ZTS Zoetis Inc | 12.72 | 10.2% | 10.2% | 11.9% |
| PAHC Phibro Animal Health Corp | 13.05 | 1,883.3% | -0.6% | 7.5% |
| MRK Merck & Co Inc | 33.5 | 8% | 8.4% | 21.2% |
| ADM Archer-Daniels-Midland Co | 34.01 | -39.1% | -33.9% | -6.7% |
| LLY ELI LILLY & Co | 39.27 | 95.6% | 49.2% | 27.5% |
| ICCC Immucell Corp | N/A | 53.8% | N/A | N/A |
All data is based on quarterly TTM periods, unless otherwise specified.